Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daron G Ferris

Showing results (71-80 of 93) with videos related to

Pageof 10
Sort By:
Gynecologic Oncology|January 21, 2020
Better survival is observed in cervical cancer patients positive for specific anti-glycan antibodies and receiving brachytherapySharad Purohit, Daron G Ferris, Manual Alvarez, et al.
Vaccine|July 9, 2013
Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in malesStephen E Goldstone, Heiko Jessen, Joel M Palefsky, et al.
Clinical and Vaccine Immunology : CVI|December 14, 2011
Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years oldRichard J Hillman, Anna R Giuliano, Joel M Palefsky, et al.
International Journal of Cancer|May 28, 2010
The accuracy of colposcopic biopsy: analyses from the placebo arm of the Gardasil clinical trialsMark H Stoler, Michelle D Vichnin, Alex Ferenczy, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 9, 2011
Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearanceRalph P Insinga, Gonzalo Perez, Cosette M Wheeler, et al.
Lancet (London, England)|November 16, 2004
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trialDiane M Harper, Eduardo L Franco, Cosette Wheeler, et al.
International Journal of Cancer|April 15, 2011
Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infectionRichard M Haupt, Cosette M Wheeler, Darron R Brown, et al.
Clinical and Vaccine Immunology : CVI|April 13, 2007
Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccinesSuzanne M Garland, Marc Steben, Mauricio Hernandez-Avila, et al.
The Journal of Infectious Diseases|December 15, 2010
External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continentsEftyhia Vardas, Anna R Giuliano, Stephen Goldstone, et al.
The Journal of Infectious Diseases|December 15, 2010
Prevalence of and risk factors for human papillomavirus (HPV) infection among HIV-seronegative men who have sex with menStephen Goldstone, Joel M Palefsky, Anna R Giuliano, et al.
Pageof 10

Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
Gynecologic Oncology|January 21, 2020
Better survival is observed in cervical cancer patients positive for specific anti-glycan antibodies and receiving brachytherapySharad Purohit, Daron G Ferris, Manual Alvarez, et al.
Vaccine|July 9, 2013
Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in malesStephen E Goldstone, Heiko Jessen, Joel M Palefsky, et al.
Clinical and Vaccine Immunology : CVI|December 14, 2011
Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years oldRichard J Hillman, Anna R Giuliano, Joel M Palefsky, et al.
International Journal of Cancer|May 28, 2010
The accuracy of colposcopic biopsy: analyses from the placebo arm of the Gardasil clinical trialsMark H Stoler, Michelle D Vichnin, Alex Ferenczy, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 9, 2011
Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearanceRalph P Insinga, Gonzalo Perez, Cosette M Wheeler, et al.
Lancet (London, England)|November 16, 2004
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trialDiane M Harper, Eduardo L Franco, Cosette Wheeler, et al.
International Journal of Cancer|April 15, 2011
Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infectionRichard M Haupt, Cosette M Wheeler, Darron R Brown, et al.
Clinical and Vaccine Immunology : CVI|April 13, 2007
Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccinesSuzanne M Garland, Marc Steben, Mauricio Hernandez-Avila, et al.
The Journal of Infectious Diseases|December 15, 2010
External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continentsEftyhia Vardas, Anna R Giuliano, Stephen Goldstone, et al.
The Journal of Infectious Diseases|December 15, 2010
Prevalence of and risk factors for human papillomavirus (HPV) infection among HIV-seronegative men who have sex with menStephen Goldstone, Joel M Palefsky, Anna R Giuliano, et al.
Pageof 10